Lampalizumab (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 By RnRMarketResearch
Browse more reports on Pharmaceuticals at http://www.rnrmarketresearch.com/reports/lifesciences/pharmaceuticals Š http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Lampalizumab (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023
Lampalizumab, also known as anti-factor D (as well as RG7417 by Roche and as FCFD4514S by its subsidiary, Genentech), is an antigen-binding fragment of a humanized mAb that targets complement factor D, the rate-limiting enzyme involved in the activation of the alternative complement pathway. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
Š http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Lampalizumab (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023 Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Complete Report is available at http://www.rnrmarketresearch.com/lampalizumab-macular-edema-andmacular-degeneration-forecast-and-market-analysis-to-2023-marketreport.html . Š http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Lampalizumab (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023 Scope: Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Lampalizumab including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Lampalizumab for the top country from 2013 to 2023. Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan. Š http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Lampalizumab (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023 Reasons to Buy:
• Understand and capitalize by identifying products that are most likely to ensure a robust return. • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration. • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential. • Make more informed business decisions from insightful and indepth analysis of Lampalizumab performance. • Obtain sales forecast for Lampalizumab from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Lampalizumab (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023 Table of Contents: 1 Table of Contents 6 1.1 List of Tables 9 1.2 List of Figures 10 2 Introduction 11 2.1 Related Reports 12 3 Disease Overview 14 3.1 Macular Degeneration Overview 14 3.1.1 Etiology and Pathophysiology 16 3.1.2 Classification 20 3.1.3 Symptoms and Diagnosis 22 3.2 Macular Edema Overview 25
Š http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Lampalizumab (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023 For more details contact Mr. Ritesh Tiwari : sales@rnrmarketresearch.com / +18883915441
RnRMarkertResearch RnRMarketResearch.com, an online repository of market research reports, offers in-depth analysis of over 5000 market segments. RnR Market Research library has syndicated reports by leading market research publishers across the globe.
Š http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441